Literature DB >> 12175753

Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats.

Makoto Kamada1, Fumitoshi Hirayama, Koichi Udo, Hideki Yano, Hidetoshi Arima, Kaneto Uekama.   

Abstract

6(A)-O-[2-(3-Benzoylphenyl)propinoyl]-alpha-cyclodextrin (KP-alpha-CyD conjugate), in which an anti-inflammatory drug, ketoprofen (KP), is covalently bound to one of the primary hydroxyl groups of alpha-cyclodextrin, was prepared, and its release behavior in vitro and in vivo was investigated. Further, the CyD conjugate-based repeated- and prolonged-release systems were designed by combining the conjugate (used as a delayed-release fraction) with the KP-2-hydroxypropyl-beta-CyD (HP-beta-CyD) complex (used as a fast-release fraction) or with KP-ethylcellulose (EC) solid dispersion (used as a slow-release fraction), respectively. The conjugate released KP only in rat cecum and colonic contents, whereas it was stable in other biological fluids of rats. The conjugate showed a typical delayed-release pattern after oral administration to rats, i.e., plasma levels of KP increased after a lag time of about 3 h and reached a maximum concentration at about 7 h. On the other hand, the non-covalent inclusion complex of KP with HP-beta-CyD gave a rapid increase in plasma drug levels, and the KP-EC solid dispersion retarded slightly the increase of plasma levels. The co-administration of the conjugate and the HP-beta-CyD complex gave a typical repeated release profile, i.e., double peaks were observed at about 1-2 and 8-12 h in plasma KP levels. On the other hand, the co-administration of the conjugate and the EC solid dispersion gave a typical sustained-release pattern of KP, i.e., a constant plasma KP level was maintained for at least 24 h. These repeated or long circulating release patterns in plasma KP levels after oral administration were clearly reflected in the anti-inflammatory effect using rats with carageenan-induced acute edema in paw. The results suggest that various release-controlled preparations can be designed by employing CyD conjugates in combination with other carriers with different releasing properties.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175753     DOI: 10.1016/s0168-3659(02)00171-2

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

1.  Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. preparation and properties of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: a technical note.

Authors:  Sanjula Baboota; Mona Dhaliwal; Kanchan Kohli
Journal:  AAPS PharmSciTech       Date:  2005-09-20       Impact factor: 3.246

2.  Physico-chemical characterization and in vitro dissolution assessment of clonazepam-cyclodextrins inclusion compounds.

Authors:  Rakesh Patel; Nirav Purohit
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

Review 3.  Advanced technologies for oral controlled release: cyclodextrins for oral controlled release.

Authors:  Paulo José Salústio; Patrícia Pontes; Claúdia Conduto; Inês Sanches; Catarina Carvalho; João Arrais; Helena M Cabral Marques
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

4.  Cyclodextrins in delivery systems: Applications.

Authors:  Gaurav Tiwari; Ruchi Tiwari; Awani K Rai
Journal:  J Pharm Bioallied Sci       Date:  2010-04

5.  Synthesis and properties of macrocyclic butanoic acid conjugates as a promising delivery formulation for the nutrition of colon.

Authors:  Jingui Cheng; Benpeng Li; Peipei Ma; Mengying Liu; Zhizhong Wang
Journal:  ScientificWorldJournal       Date:  2013-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.